1
|
Castaño-Vinyals G, Sadetzki S, Vermeulen R, Momoli F, Kundi M, Merletti F, Maslanyj M, Calderon C, Wiart J, Lee AK, Taki M, Sim M, Armstrong B, Benke G, Schattner R, Hutter HP, Krewski D, Mohipp C, Ritvo P, Spinelli J, Lacour B, Remen T, Radon K, Weinmann T, Petridou ET, Moschovi M, Pourtsidis A, Oikonomou K, Kanavidis P, Bouka E, Dikshit R, Nagrani R, Chetrit A, Bruchim R, Maule M, Migliore E, Filippini G, Miligi L, Mattioli S, Kojimahara N, Yamaguchi N, Ha M, Choi K, Kromhout H, Goedhart G, 't Mannetje A, Eng A, Langer CE, Alguacil J, Aragonés N, Morales-Suárez-Varela M, Badia F, Albert A, Carretero G, Cardis E. Wireless phone use in childhood and adolescence and neuroepithelial brain tumours: Results from the international MOBI-Kids study. Environ Int 2022; 160:107069. [PMID: 34974237 DOI: 10.1016/j.envint.2021.107069] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Revised: 12/22/2021] [Accepted: 12/24/2021] [Indexed: 06/14/2023]
Abstract
In recent decades, the possibility that use of mobile communicating devices, particularly wireless (mobile and cordless) phones, may increase brain tumour risk, has been a concern, particularly given the considerable increase in their use by young people. MOBI-Kids, a 14-country (Australia, Austria, Canada, France, Germany, Greece, India, Israel, Italy, Japan, Korea, the Netherlands, New Zealand, Spain) case-control study, was conducted to evaluate whether wireless phone use (and particularly resulting exposure to radiofrequency (RF) and extremely low frequency (ELF) electromagnetic fields (EMF)) increases risk of brain tumours in young people. Between 2010 and 2015, the study recruited 899 people with brain tumours aged 10 to 24 years old and 1,910 controls (operated for appendicitis) matched to the cases on date of diagnosis, study region and age. Participation rates were 72% for cases and 54% for controls. The mean ages of cases and controls were 16.5 and 16.6 years, respectively; 57% were males. The vast majority of study participants were wireless phones users, even in the youngest age group, and the study included substantial numbers of long-term (over 10 years) users: 22% overall, 51% in the 20-24-year-olds. Most tumours were of the neuroepithelial type (NBT; n = 671), mainly glioma. The odds ratios (OR) of NBT appeared to decrease with increasing time since start of use of wireless phones, cumulative number of calls and cumulative call time, particularly in the 15-19 years old age group. A decreasing trend in ORs was also observed with increasing estimated cumulative RF specific energy and ELF induced current density at the location of the tumour. Further analyses suggest that the large number of ORs below 1 in this study is unlikely to represent an unknown causal preventive effect of mobile phone exposure: they can be at least partially explained by differential recall by proxies and prodromal symptoms affecting phone use before diagnosis of the cases. We cannot rule out, however, residual confounding from sources we did not measure. Overall, our study provides no evidence of a causal association between wireless phone use and brain tumours in young people. However, the sources of bias summarised above prevent us from ruling out a small increased risk.
Collapse
Affiliation(s)
- G Castaño-Vinyals
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - S Sadetzki
- Cancer & Radiation Epidemiology Unit, Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Ministry of Health, Jerusalem, Israel
| | - R Vermeulen
- Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| | - F Momoli
- School of Epidemiology and Public Health, University of Ottawa, Canada; Risk Science International, Ottawa, Canada
| | - M Kundi
- Department of Environmental Health, Center for Public Health, Medical University Vienna, Austria
| | - F Merletti
- Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Turin, Italy
| | | | | | - J Wiart
- Laboratoire de Traitement et Communication de l'Information (LTCI), Telecom Paris, Institut Polytechnique de Paris, 91120 Palaiseau, France
| | - A-K Lee
- Radio Technology Research Department, Electronics and Telecommunications Research Institute (ETRI), Yuseong-gu, Daejeon, Korea
| | - M Taki
- Department of Electrical & Electronic Engineering, Graduate Schools of Science and Engineering, Tokyo Metropolitan University, Tokyo, Japan
| | - M Sim
- School of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia
| | - B Armstrong
- School of Population and Global Health, The University of Western Australia, Perth 6009, Australia
| | - G Benke
- School of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia
| | - R Schattner
- School of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia
| | - H-P Hutter
- Department of Environmental Health, Center for Public Health, Medical University Vienna, Austria
| | - D Krewski
- Risk Science International, Ottawa, Canada; School of Epidemiology and Public Health, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada; McLaughlin Centre for Population Health Risk Assessment, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
| | - C Mohipp
- University of Ottawa, Ottawa, Canada
| | - P Ritvo
- York University, Toronto, Ontario, Canada
| | - J Spinelli
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
| | - B Lacour
- French National Registry of Childhood Solid Tumors, CHRU, Nancy, France; Inserm UMR 1153, Center of Research in Epidemiology and StatisticS (CRESS), Paris University, Epidemiology of Childhood and Adolescent Cancers Team (EPICEA), Paris, France
| | - T Remen
- Inserm UMR 1153, Center of Research in Epidemiology and StatisticS (CRESS), Paris University, Epidemiology of Childhood and Adolescent Cancers Team (EPICEA), Paris, France
| | - K Radon
- Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany
| | - T Weinmann
- Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany
| | - E Th Petridou
- Hellenic Society for Social Pediatrics & Health Promotion, Greece; Dept of Hygiene and Epidemiology, Medical School, National and Kapodistrian University of Athens, Greece
| | - M Moschovi
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - A Pourtsidis
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - K Oikonomou
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - P Kanavidis
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - E Bouka
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - R Dikshit
- Centre for Cancer Epidemiology, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India
| | - R Nagrani
- Centre for Cancer Epidemiology, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstrasse 30, 28359 Bremen, Germany
| | - A Chetrit
- Cancer & Radiation Epidemiology Unit, Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Tel-Hashomer, Israel
| | - R Bruchim
- Cancer & Radiation Epidemiology Unit, Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Tel-Hashomer, Israel
| | - M Maule
- Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Turin, Italy
| | - E Migliore
- Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Turin, Italy
| | - G Filippini
- Scientific Director's Office, Carlo Besta Foundation and Neurological Institute, Milan, Italy
| | - L Miligi
- Environmental and Occupational Epidemiology Branch, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy
| | - S Mattioli
- Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Italy
| | - N Kojimahara
- Department of Public Health, Tokyo Women's Medical University, Tokyo, Japan; Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan
| | - N Yamaguchi
- Department of Public Health, Tokyo Women's Medical University, Tokyo, Japan; Saiseikai Research Institute of Care and Welfare, Tokyo, Japan
| | - M Ha
- Department of Preventive Medicine, Dankook University College of Medicine, 119 Dandae-ro, Cheonan, Chungnam, South Korea
| | - K Choi
- Department of Preventive Medicine, Dankook University College of Medicine, 119 Dandae-ro, Cheonan, Chungnam, South Korea
| | - H Kromhout
- Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| | - G Goedhart
- Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| | - A 't Mannetje
- Centre for Public Health Research, Massey University, Wellington, New Zealand
| | - A Eng
- Centre for Public Health Research, Massey University, Wellington, New Zealand
| | - C E Langer
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain
| | - J Alguacil
- CIBER Epidemiologia y Salud Pública, Madrid, Spain; Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - N Aragonés
- CIBER Epidemiologia y Salud Pública, Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, 28035 Madrid, Spain
| | - M Morales-Suárez-Varela
- CIBER Epidemiologia y Salud Pública, Madrid, Spain; Unit of Public Health and Environmental Care, Department of Preventive Medicine and Public Health, Food Sciences, Toxicology and Forensic Medicine, University of Valencia, Valencia, Spain
| | - F Badia
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain; Institut Cartogràfic i Geològic de Catalunya, Barcelona, Spain
| | - A Albert
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain
| | - G Carretero
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - E Cardis
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain.
| |
Collapse
|
8
|
Kosmidis SP, Baka M, Bouhoutsou D, Kallergi C, Doganis D, Douladiris N, Varvoutsi M, Pourtsidis A, Sotiropoulou A, Papageirgiou PS, Kosmidis HV. Immunological recovery in children with ALL at the end of intensive therapy, at the completion of therapy, and up to one year off therapy. A follow-up study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9031 Background: Children undergoing therapy for ALL are known to have impaired immune function. (ASCO 2005, abstract #8541). Methods: We prospectively evaluated the humoral and cellular immunity in children with ALL at the end of intensive therapy (Evaluation 1 -E1) and values were compared to those at the completion of therapy (E2), at 6 months (E3) and at 12 months thereafter (E4). Investigations among others included CBC, lymphocyte subpopulation by flow cytometry (CD3, CD4, CD8, CD16, CD19, CD3 DR, CD45RO and CD45RA), immunoglobulin levels by nephelometry, antibody titers to MMR immunization and skin tests to Candida, Trichophyton, diphtheria toxin and tetanus toxoid. Seventy three children with ALL, 48 boys, 25 girls (median age 4 years on diagnosis) treated according to BFM 95 protocol were evaluated. Of the 139 evaluations, 41 were E1, 43 E2, 37 E3, 18 E4 and data were analyzed with a non parametric Mann Whitney test. Results: Immunoglobulin levels at E1 were low in the majority of children and were increasing at E2 and E3 and E4 for IgA and IgM (median values of parameters studied are shown in the table in mg/dl for immunoglobulins and % for CD’s). Of the 70 children immunized with MMR only 11 had absent IgG antibodies. Also, skin tests were positive for tetanus toxoid in 93/139 evaluations, for candida in 41/139 and negative for trichophyton and diphtheria toxin. Conclusions: Children with leukemia experience severe immunological damage after intensive therapy which is gradually improving overtime although some values remain abnormal 6 months after the completion of therapy. It is worth mentioning that despite impaired immune function serious infections were not documented after the first six months of intensive therapy. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. P. Kosmidis
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - M. Baka
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - D. Bouhoutsou
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - C. Kallergi
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - D. Doganis
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - N. Douladiris
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - M. Varvoutsi
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - A. Pourtsidis
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - A. Sotiropoulou
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - P. S. Papageirgiou
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| | - H. V. Kosmidis
- Radiation Oncology Dept. Saint Savas Hospital, Athens, Greece; Oncology Dept Children’s Hospital Aglai Kyriakoy, Athens, Greece; Serology Lab Children’s Hospital Aglaia Kyriakoy, Athens, Greece; Athens University Department of Pediatrics, Athens, Greece
| |
Collapse
|